Clinical trials: Epidermal Growth Factor Receptor
Non-Small-Cell Lung Cancer
The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase
To evaluate Non-Small Cell Lung Cancer (NSCLC) patients clinical profile and the outcome after treatment with Gefitinib in Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital, Surabaya, Indonesia.
- Trial name
- EVALUATE (NCT02755337)
- Where
- Indonesia
- Volunteers
- 70 people
- Sponsor
- Dr. Soetomo General Hospital
Stomach Neoplasms
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin…
- Trial name
- HER2 (NCT02136836)
- Where
- South Korea
- Volunteers
- 860 people
- Sponsor
- Yonsei University
Non-Small Cell Lung Cancer
Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer
Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be performed. The detection rates of EGFR mutation will be compared using paired samples.
- Trial name
- SPACE (NCT01767974)
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Chonnam National University Hospital
Solid Tumours, CNS Tumours
A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR
This is an open-label, sequential dose exploration study of single agent EEDVSMit administered by intravenous (IV) infusion twice weekly, followed by weekly maintenance dosing, in children with recurrent/refractory solid or CNS…
- Trial name
- ECREST (NCT02687386)
- Testing
- Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)
- Where
- 2 sites in Australia
- Volunteers
- 9 people
- Sponsor
- Dr David Ziegler
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Colorectal Cancer, Quality of Life
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can target tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00079066
- Testing
- cetuximab, quality-of-life assessment
- Where
- 33 sites in Australia, Canada
- Volunteers
- 572 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small-Cell Lung Carcinoma
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer
Background: Research has shown that the Epidermal Growth Factor Receptor (EGFR) gene is an important target for personalized lung cancer treatment.
- Trial name
- NCT01255150
- Where
- 12 sites in United States, Bolivia and 3 more
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Tumor Growth Factors in Hepatocellular Carcinoma
Malignant cells frequently produce many tumor growth factors to autocidal or endocrinal proliferate growth, metastasis,or angiogenesis about tumor cells.
- Trial name
- NCT00764140
- Testing
- tumor growth factor concentration
- Where
- Taiwan
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Lung Neoplasms
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
Lung cancer is the leading cause of cancer-related death worldwide and is well known to remain a major health problem. Non-small-cell lung cancer (NSCLC) constitutes more than 80% of all the cases of lung cancer.
- Trial name
- NCT01775943
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Ulsan University Hospital
Refractory Germ Cell Tumors Expressing EGRF
A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
This study will evaluate the use of ZD1839 in the treatment of subjects with refractory germ cell tumors. Subjects will take ZD1839 for one year in the absence of excessive toxicity or decision to withdraw.
- Trial name
- IUCRO-0021 (NCT00198159)
- Testing
- ZD1839 Iressa
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Indiana University
Is Targeted Therapy Increasing Survival Inoperable Nonsmall Cell Lung Cancer With Spinal Metastasis ?
Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?
Not significantly increased survival in T/T
- Trial name
- NCT02740894
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea
This study is designed to gather epidemiological data in Korea on HER2 incidence in gastric and gastroesophageal junction cancer as assessed by local laboratories in a real-life setting.
- Trial name
- NCT02538562
- Where
- 14 sites in South Korea
- Volunteers
- 1,695 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)
The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study drug") in a real world setting in adult patients with advanced or metastatic, epidermal growth…
- Trial name
- KOREA (NCT02777567)
- Where
- South Korea
- Volunteers
- 315 people
- Sponsor
- AstraZeneca
ER/PR(+), Her2(-) Breast Cancer
Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan
Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305…
- Trial name
- NCT02924584
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Pancreatic Adenocarcinoma
HER-2 Expression in Pancreatic Duct Adenocarcinoma
Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their…
- Trial name
- NCT06055647
- Testing
- immunohistochemical approach
- Volunteers
- 37 people
- Sponsor
- Sohag University
Invasive Breast Cancer
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
This is a prospective, single-center, non-randomized, non-controlled study. The estrogen receptor (ER), progesterone receptor (PgR), HER2 status and Ki67 index of CNB specimen are critical biomarkers for making neoadjuvant…
- Trial name
- NCT02773784
- Testing
- immunohistochemistry and/or FISH
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Peking University
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
This phase I/II trial studies the side effects and best dose of gefitinib when given together with radiation therapy and to see how well it works in treating patients with glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00052208
- Testing
- gefitinib, radiation therapy, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC
A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
To determine EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC. To determine the association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.
- Trial name
- NCT01100827
- Testing
- EGFR mutation status in patients
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Colorectal Neoplasm
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
This is an observational, non-interventional, uncontrolled, multicentric safety study in subjects with epidermal growth factor receptor (EGFR)-expressing, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type…
- Trial name
- NCT01074333
- Testing
- Cetuximab
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastric Cancer, Gastroesophageal Junction Cancer
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
The primary objective is to evaluate the concordance between human epidermal growth factor receptor 2 (HER2) status determined by the participating laboratory and by the centralized laboratory.
- Trial name
- NCT02731313
- Testing
- Trastuzumab
- Where
- 19 sites in France
- Volunteers
- 420 people
- Sponsor
- Hoffmann-La Roche